BofA downgrades Lineage to Underperform on weak demand, lack of visibility

As previously reported, BofA downgraded Lineage (LINE) to Underperform from Neutral with a price target of $42, down from $47, citing ongoing demand challenges, persistent macro uncertainty, cautiousness about occupancy growth, and limited visibility into multiple headwinds impacting the sector, including tariffs, interest rates, excess capacity, GLP1 drugs and government benefit reductions. The firm, which expects weaker demand to persist into 2026, cut its assumptions for 2025 and 2026 occupancy growth.